These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

86 related articles for article (PubMed ID: 8523973)

  • 1. [Viral validation of the bio-globulin production process].
    Zahorska R; Buchowicz I
    Med Dosw Mikrobiol; 1995; 47(1-2):89-94. PubMed ID: 8523973
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Viral safety of Nanogam, a new 15 nm-filtered liquid immunoglobulin product.
    Terpstra FG; Parkkinen J; Tölö H; Koenderman AH; Ter Hart HG; von Bonsdorff L; Törmä E; van Engelenburg FA
    Vox Sang; 2006 Jan; 90(1):21-32. PubMed ID: 16359352
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Concentrate of coagulation factor IX: viral validation of the thermoinactivation process].
    Zahorska R; Buchowicz I; Ejduk A
    Acta Haematol Pol; 1995; 26(4):421-4. PubMed ID: 8571744
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Inactivation kinetics of model and relevant blood-borne viruses by treatment with sodium hydroxide and heat.
    Borovec S; Broumis C; Adcock W; Fang R; Uren E
    Biologicals; 1998 Sep; 26(3):237-44. PubMed ID: 10208725
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Inactivation and clearance of viruses during the manufacture of high purity factor IX.
    Johnston A; Macgregor A; Borovec S; Hattarki M; Stuckly K; Anderson D; Goss NH; Oates A; Uren E
    Biologicals; 2000 Sep; 28(3):129-36. PubMed ID: 10964439
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Iodine-mediated inactivation of lipid- and nonlipid-enveloped viruses in human antithrombin III concentrate.
    Highsmith F; Xue H; Chen X; Benade L; Owens J; Shanbrom E; Drohan W
    Blood; 1995 Jul; 86(2):791-6. PubMed ID: 7606009
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Inactivation of virus in intravenous immunoglobulin G using solvent/detergent treatment and pasteurization.
    Aghaie A; Pourfatollah AA; Bathaie SZ; Moazzeni SM; Khorsand Mohammad Pour H; Sharifi Z
    Hum Antibodies; 2008; 17(3-4):79-84. PubMed ID: 19029665
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Preventing the spread of hepatitis B and C viruses: where are germicides relevant?
    Sattar SA; Tetro J; Springthorpe VS; Giulivi A
    Am J Infect Control; 2001 Jun; 29(3):187-97. PubMed ID: 11391281
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Virus reduction in the preparation of intravenous immune globulin: in vitro experiments.
    Chandra S; Cavanaugh JE; Lin CM; Pierre-Jerome C; Yerram N; Weeks R; Flanigan E; Feldman F
    Transfusion; 1999 Mar; 39(3):249-57. PubMed ID: 10204586
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Inactivation of lipid enveloped viruses by octanoic Acid treatment of immunoglobulin solution.
    Dichtelmüller H; Rudnick D; Kloft M
    Biologicals; 2002 Jun; 30(2):135-42. PubMed ID: 12127315
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Evaluation of viral safety of a high-purity human factor VIII concentrate submitted to 2 specific virus inactivation treatments (FANDHI)].
    Ristol P; Gensana M; Fernández J; Massot M; Biescas H; Darling A; Jorquera JI; Vericat F
    Sangre (Barc); 1996 Apr; 41(2):131-6. PubMed ID: 9045353
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The viral safety of intravenous immune globulin.
    Yap PL
    Clin Exp Immunol; 1996 May; 104 Suppl 1():35-42. PubMed ID: 8625542
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Investigations of prion and virus safety of a new liquid IVIG product.
    Stucki M; Boschetti N; Schäfer W; Hostettler T; Käsermann F; Nowak T; Gröner A; Kempf C
    Biologicals; 2008 Jul; 36(4):239-47. PubMed ID: 18337119
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Assessment of viral inactivation during pH 3.3 pepsin digestion and caprylic acid treatment of antivenoms.
    Burnouf T; Terpstra F; Habib G; Seddik S
    Biologicals; 2007 Oct; 35(4):329-34. PubMed ID: 17363271
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prevalence of hepatitis B, C, and delta virus infections among children in Mongolia: progress in childhood immunization.
    Tsatsralt-Od B; Takahashi M; Endo K; Agiimaa D; Buyankhuu O; Ninomiya M; Lorenzo FR; Okamoto H
    J Med Virol; 2007 Aug; 79(8):1064-74. PubMed ID: 17596839
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Partitioning and inactivation of viruses by the caprylic acid precipitation followed by a terminal pasteurization in the manufacturing process of horse immunoglobulins.
    Mpandi M; Schmutz P; Legrand E; Duc R; Geinoz J; Henzelin-Nkubana C; Giorgia S; Clerc O; Genoud D; Weber T
    Biologicals; 2007 Oct; 35(4):335-41. PubMed ID: 17470396
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Evidence of multiple hepatitis virus infections in autopsied materials of intravenous drug addicts.
    Schleicher S; Schieffer M; Jürgens S; Wehner HD; Flehmig B
    Ig Sanita Pubbl; 2005; 61(5):435-50. PubMed ID: 17214028
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Role of hepatitis B, C, and D viruses in dual and triple infection: influence of viral genotypes and hepatitis B precore and basal core promoter mutations on viral replicative interference.
    Jardi R; Rodriguez F; Buti M; Costa X; Cotrina M; Galimany R; Esteban R; Guardia J
    Hepatology; 2001 Aug; 34(2):404-10. PubMed ID: 11481626
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Virus validation studies of immunoglobulin preparations.
    Biesert L
    Clin Exp Rheumatol; 1996; 14 Suppl 15():S47-52. PubMed ID: 8828948
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pasteurized, monoclonal antibody factor VIII concentrate: establishing a new standard for purity and viral safety of plasma-derived concentrates.
    Goldsmith JC
    Blood Coagul Fibrinolysis; 2000 Mar; 11(2):203-15. PubMed ID: 10759015
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.